Ergomed : FDA removal of hold on Ph3 trial with Multikine

PRESS RELEASE

Ergomed notes announcement by co-development partner, CEL-SCI, of FDA removal of clinical hold on Phase 3 clinical trial with Multikine in head and neck cancer

London, UK - 14 August 2017:Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a specialised pharmaceutical services and drug development company, notes that its co-development partner CEL-SCI has announced that the US Food and Drug Administration (FDA) has removed the clinical hold on the current Phase 3 study with Multikinein head and neck cancer.

All clinical trial activities can now be resumed. Nine-hundred and twenty-eight (928) newly diagnosed head and neck cancer patients have been enrolled in this Phase 3 study and all the patients who have completed treatment continue to be followed for protocol-specific outcomes in accordance with the Study Protocol.

Dr. Dan Weng, Chief Executive Officer of Ergomed, said: 'We're very pleased to hear that the Phase 3 study of Multikine in head and neck cancer has been approved for continuation by the FDA. Multikine addresses a significant unmet medical need and we look forward to continuing to work with CEL-SCI on what is the largest ever Phase III study in head and neck cancer.'

The full announcement from CEL-SCI can be found on its website: www.cel-sci.com.

ENDS

Enquiries:

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit:http://ergomedplc.com.